Citations

Clear

10 citation(s) found for "Blazek, Audrey".

Changes in Patient Outcomes after Evaluation at a Tertiary Dedicated Ataxia Clinic (P4-16.014)
Ramsay, Audrey Blazek, Coon, Elizabeth, Vairo, Filippo Pinto e, Jackson, Lauren, Blazek, Audrey M. , Coon, Elizabeth A. , Jackson, Lauren

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217426 Get It

Parkinsonian Phenotypes in Down Syndrome: A Potentially Reversible Cause of Parkinsonism (P7-17.009)
Ramsay, Audrey Blazek, Liu, Tina, Coffman, Keith, Savica, Rodolfo , Blazek, Audrey M.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217406 Get It

Peripheral nerves can serve as a sanctuary for lymphoma
Jones, Felipe J S , Spinner, Robert J, Engelstad, JaNean, Blazek, Audrey M. , Amrami, Kimberly K, Pinto, Marcus Vinícius , Jones, Felipe J.S. , Pinto, Marcus V , Spinner, Robert J. , Engelstad, JaNean , Amrami, Kimberly K.

Mayo Clinic

Practical Neurology | April 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: pn-2025-005041

10.1136/pn-2025-005041 | PMID 42049493 Get It

Gait Analysis in Neurologic Disorders
Ali, Farwa , Padilla, Hannah, Blazek, Audrey M. , Barnard, Leland R , Barnard, Leland , Kaufman, Kenton R.

Mayo Clinic

Neurology | September 19, 2025 | Volume: 105 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000214154 | PMID 40971743 Get It

Hydroxychloroquine Leading to Myopathy with Bulbar Involvement in an 80-year-old (P7-11.009)
Rigler, Nicole, Heshcke, Rachel, Blazek, Audrey M.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211036 Get It

Gadolinium Enhancement Patterns in Leptomeningeal Disease (P2-2.001)
Blazek, Audrey, Carabenciov, Ivan D.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210453 Get It

A 63 year-Old Male With a Painful Subacute Demyelinating Neuropathy
Blazek, Audrey M. , Griffin, Kim, Skolka, Michael, Toledano, Michel , Blazek Ramsay, Audrey , Pinto, Marcus Vinícius

Mayo Clinic

The Neurohospitalist | January 11, 2025 | Volume: 15 | Issue: 3 | Pages: 291-295

10.1177/19418744251314540 | PMID 39803330 Get It

Subacute, painful weakness is a common problem encountered by neurologists and can be associated with systemic symptoms. The patient presented with 6 weeks of progressive neuropathic pain followed by sensory changes and distal-predominant weakness. This case reviews the broad differential for such a presentation and a comprehensive, stepwise approach to diagnosis. Particular attention is paid to the potentially treatable polyradiculoneuropathies, including more recently recognized immune-mediated etiologies. Through this stepwise approach, we review how a definitive diagnosis was made.
NCMP-02. BIOPSY OUTCOMES OF PATIENTS WITH SUSPECTED LEPTOMENINGEAL CARCINOMATOSIS: A RETROSPECTIVE CASE SERIES
Blazek, Audrey, Carabenciov, Ivan D.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v207-v207

10.1093/neuonc/noad179.0786 Get It

Abstract BACKGROUND Leptomeningeal carcinomatosis is commonly considered when patients present with meningeal enhancement on magnetic resonance imaging (MRI), even without a known primary malignancy. In practice, some clinicians advocate for early meningeal biopsy to expedite diagnosis, citing lack of specificity of other testing, such as cerebrospinal fluid (CSF) analysis. METHODS We identified a cohort of patients with meningeal enhancement that underwent biopsy for diagnostic purposes between 2010 and 2022. Presenting symptoms, physical exam, enhancement pattern on MRI, other imaging findings, CSF parameters, other laboratory results, final diagnosis, and recommended treatment were recorded when available. RESULTS Out of nearly 100 cases included, the majority were autoimmune or inflammatory in etiology. Only 13 patients were diagnosed with malignancy-related enhancement, and 10 of these cases were felt to be true carcinomatosis. Nine out of the 13 patients were diagnosed with lymphoma. Four of these lymphomas were diagnosed on systemic biopsy, with meningeal biopsies negative for malignant cells. The other malignancies included systemic adenocarcinoma, oligodendroglioma, and a rare hematologic cancer. Nearly all 13 patients had abnormal CSF parameters, notably pleocytosis, but none had malignant cells in the fluid. Most frequent presenting symptoms were encephalopathy, vision changes, and strength/sensory changes. MRI often showed cranial nerve or general cerebral and cerebellar involvement, and physical exam often showed cranial nerve, strength, and sensory deficits. All patients proceeded with chemotherapy after diagnosis. CONCLUSIONS When leptomeningeal carcinomatosis is considered based on MRI enhancement, the clinical approach should continue to revolve around indirect testing such as CSF analysis, serum studies, and other imaging techniques to consider alternative biopsy sites before pursuing direct sampling with meningeal biopsy. With this approach, many patients with suspected carcinomatosis can avoid undergoing meningeal biopsy and decrease the chance of treatment delay.
Combined Prophylaxis of Chronic Migraine with OnabotulinumtoxinA and Anti-CGRP Antibodies
Blazek, Audrey

Mayo Clinic

Annals Of Headache Medicine Journal | September 5, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.30756/ahmj.2023.11.01 Get It

Objective: To evaluate the efficacy of adding large molecule anti-calcitonin gene-related peptide monoclonal antibodies (mAbs) to onabotulinumtoxinA (OBT-A) for chronic migraine prevention. Background: Chronic migraine (CM) is a highly prevalent, debilitating disorder that leads to personal, social, and economic burdens. Both OBT-A and mAbs are proven safe and effective in chronic migraine prevention. The use of combination therapy has not been formally studied but may prove more effective than either monotherapy alone in select patients. Methods: This is a retrospective chart review of patients with chronic migraine, treated with OBT-A, who received additional mAb preventative therapy. The primary endpoint was migraine headache days per month (MHD) after 3 months of combined therapy. Secondary endpoints included total headache days per month, headache intensity, disability level, and use of abortive medications. Results: Of 1503 patients reviewed, 133 met inclusion criteria. At 3 months of combined therapy, mean reduction of MHD from baseline was 6.2 (95% CI 4.91 to 7.49, p < 0.0001). Nearly 2/3rd of patients (60.9%) experienced ≥ 50% MHD reduction. Fewer patients reported high disability level (14.6% [17/126], compared to 29.4%) and high headache intensity (13.0% [16/119], compared to 51.3%) at 3 months (all p < 0.0001). A reduction in abortive medication doses needed and discontinuation of concomitant oral preventative medications was also noted in 15.8% and 6.8% of patients, respectively. Conclusions: Combined therapy with OBT-A and mAbs is well-tolerated, effective in further reducing migraine frequency, and may improve quality of life for patients with CM refractory to monotherapy.